Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > mid-month ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jul 09, 2021 11:55pm
232 Views
Post# 33525950

RE:RE:mid-month ...

RE:RE:mid-month ...
CandyC wrote:
MrMugsy wrote: We've got mid-month fast approaching.
That's when we're supposed to get a Letter to Shareholders.
If we're lucky we get it before Friday.

Looking for the wording on the NASDAQ listing ... commitment or non-commitment.
Tone on negotiations.
Also, any other updates on drug development.

Meet us halfway ... just give us one OTENA partnership by then.
I'd even take a product development partnership.

: )

 

Isn't one of the requirements for Nasdaq is to be over $3.00usd for a extended time?


It probably is $3 USD ... so ... they need to create demand.
Was watching the ask price today - if someone wanted to buy 5,000-10,000 shares at market, they would have drove the price well over $4. 
Demand doesn't exist and it hasn't existed since February.

Need the NAZ to create demand and we need the demand to get to the NAZ ... catch 22.

I think there's a plan - unfortunately time is also a factor and it's getting in the way.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities